Interview with Ellen Velisek, RN, BSN, OCN: Patient Coordination Following CAR T-Cell Therapy

Interview with Ellen Velisek, RN, BSN, OCN: Preparing Patients for CAR T-Cell Therapy

The Evolving Field of CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

American Cancer Society: CAR T-Cell Therapy and its Side Effects

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

CancerCare

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

CAR T-Cell Therapy Resource Center

Interview with Ellen Velisek, RN, BSN, OCN: Patient Coordination Following CAR T-Cell Therapy

American Cancer Society: CAR T-Cell Therapy and its Side Effects

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

CancerCare

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Frontiers in Oncology

Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis

Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Blood

How I treat HLH-like toxicities following immune effector cell therapy

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Identifying and Managing CAR T-Associated Hemophagocytic Lymphohistiocytosis Following Dual-Targeted CAR T-Cell Therapy

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Fast Facts #12: BCMA Targets